WITHDRAWN: EGFR exon 19 deletion is associated with favorable overall survival after first-line icotinib therapy in advanced non-small cell lung cancer patients: a retrospective, multiple-center, real-world study
نویسندگان
چکیده
منابع مشابه
Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
BACKGROUND A recent pooled analysis of the LUX-LUNG3 and LUX-LUNG6 trials suggested that afatinib (an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)) is especially effective against non-small cell lung cancer (NSCLC) carrying an EGFR exon 19 deletion. MATERIALS AND METHODS Stable viral transfectant HEK293 cell lines carrying an exon 19 deletion (HEK293/19 d...
متن کاملApatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
BACKGROUND Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate the efficacy and safety of apatinib plus icotinib in patients with advanced NSCLC after icotinib treatment failure. PATIENTS AND METHODS This stu...
متن کاملPostoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
BACKGROUND The aim of this retrospective study is to identify epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer patients and to compare the long-term postoperative outcomes in different EGFR-TKI-targeted therapy effects between the different EGFR mutation groups. METHODS A total of 2094 postoperative non-small cell lung cancer (NSCLC) patients with EGFR gene dete...
متن کاملIcotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
BACKGROUND Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC). METHODS 82 consecutive patients treated with icotinib as first (n = 24...
متن کاملReal-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
PURPOSE To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations. METHODS Using a nationally representative electronic health record data from the Flatiron dataset which ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2017
ISSN: 1949-2553
DOI: 10.18632/oncotarget.23720